Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives $49.94 Average PT from Brokerages

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the twenty ratings firms that are covering the company, MarketBeat reports. Eight investment analysts have rated the stock with a hold recommendation, ten have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $49.94.

APLS has been the topic of several research reports. Morgan Stanley began coverage on Apellis Pharmaceuticals in a research report on Thursday, November 21st. They issued an "equal weight" rating and a $31.00 price objective on the stock. Robert W. Baird dropped their price target on Apellis Pharmaceuticals from $92.00 to $55.00 and set an "outperform" rating on the stock in a report on Thursday, November 7th. Royal Bank of Canada reiterated a "sector perform" rating and issued a $25.00 price objective on shares of Apellis Pharmaceuticals in a research note on Monday, November 4th. JPMorgan Chase & Co. lowered their price objective on Apellis Pharmaceuticals from $64.00 to $57.00 and set an "overweight" rating on the stock in a report on Friday, September 13th. Finally, Evercore ISI raised Apellis Pharmaceuticals to a "strong-buy" rating in a report on Thursday, October 31st.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Several large investors have recently modified their holdings of APLS. Wolverine Asset Management LLC purchased a new stake in shares of Apellis Pharmaceuticals in the third quarter valued at $27,000. True Wealth Design LLC acquired a new position in Apellis Pharmaceuticals during the 3rd quarter valued at approximately $27,000. Capital Performance Advisors LLP bought a new stake in shares of Apellis Pharmaceuticals during the third quarter valued at about $56,000. KBC Group NV lifted its stake in Apellis Pharmaceuticals by 34.8% during the third quarter. KBC Group NV now owns 2,632 shares of the company's stock valued at $76,000 after purchasing an additional 679 shares during the last quarter. Finally, nVerses Capital LLC raised its stake in Apellis Pharmaceuticals by 300.0% during the 2nd quarter. nVerses Capital LLC now owns 2,800 shares of the company's stock valued at $107,000 after purchasing an additional 2,100 shares during the period. 96.29% of the stock is owned by institutional investors and hedge funds.

Apellis Pharmaceuticals Trading Up 0.2 %

NASDAQ APLS traded up $0.07 during trading on Friday, hitting $33.21. The stock had a trading volume of 3,733,222 shares, compared to its average volume of 2,007,418. The firm has a 50 day moving average price of $30.31 and a 200 day moving average price of $34.58. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91. The company has a market capitalization of $4.13 billion, a PE ratio of -16.36 and a beta of 0.94. Apellis Pharmaceuticals has a twelve month low of $24.34 and a twelve month high of $73.80.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.14). The business had revenue of $196.83 million for the quarter, compared to analyst estimates of $200.00 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The company's revenue was up 78.3% on a year-over-year basis. During the same period in the prior year, the company earned ($1.17) EPS. As a group, equities research analysts forecast that Apellis Pharmaceuticals will post -1.72 earnings per share for the current year.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).